Shares of Zoetis have dropped nearly 40% in recent years, but operations remain strong with a promising pipeline of therapies. The stock, which previously outperformed the S&P 500, is now trading at a discounted P/E ratio of 21, making it a compelling long-term buy. Zoetis continues to lead in the animal healthcare industry, with plans for major market approvals and potential blockbuster drugs. With steady dividend growth and a declining share count, Zoetis is positioned for a turnaround, especially as the global animal healthcare industry is expected to grow annually.

Read more at Nasdaq: This Could Be One of the Best Healthcare Stock Buying Opportunities I’ve Seen in Years